ProImmune unveils new in vitro cytokine release assay
By using fresh undiluted whole blood from a large cohort of donors, the ProStorm assay provides a sensitive evaluation of cytokine responses to a therapeutic in one simple
The US Food and Drug Administration (FDA) has approved AstraZeneca’s Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have refused cisplatin-based chemotherapy.